These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10595273)

  • 1. Costs and benefits of diagnosing familial breast cancer.
    Heimdal K; Maehle L; Møller P
    Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.
    Pasini B; Pierotti MA
    Dis Markers; 1999 Oct; 15(1-3):41-3. PubMed ID: 10595250
    [No Abstract]   [Full Text] [Related]  

  • 3. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
    Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
    Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of testing for breast cancer susceptibility genes.
    Holland ML; Huston A; Noyes K
    Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.
    Møller P; Evans G; Haites N; Vasen H; Reis MM; Anderson E; Apold J; Hodgson S; Eccles D; Olsson H; Stoppa-Lyonnet D; Chang-Claude J; Morrison PJ; Bevilacqua G; Heimdal K; Maehle L; Lalloo F; Gregory H; Preece P; Borg A; Nevin NC; Caligo M; Steel CM
    Dis Markers; 1999 Oct; 15(1-3):207-11. PubMed ID: 10595280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
    Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
    Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio.
    Balmaña J; Sanz J; Bonfill X; Casado A; Rué M; Gich I; Díez O; Sabaté JM; Baiget M; Alonso MC
    Int J Cancer; 2004 Nov; 112(4):647-52. PubMed ID: 15382046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe.
    Morrison PJ; Steel CM; Vasen HF; Eccles D; Evans DG; Møller P; Hodgson S; Stoppa-Lyonnet D; Chang-Claude J; Caligo M; Olah E; Haites NE; Nevin NC
    Dis Markers; 1999 Oct; 15(1-3):159-65. PubMed ID: 10595272
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
    Norum J; Hagen AI; Maehle L; Apold J; Burn J; Møller P
    Eur J Cancer; 2008 May; 44(7):963-71. PubMed ID: 18362067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
    Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
    Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
    Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
    Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
    Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
    Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
    Heimdal K; Maehle L; Apold J; Pedersen JC; Møller P
    Eur J Cancer; 2003 Oct; 39(15):2205-13. PubMed ID: 14522380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    Schrauder MG; Brunel-Geuder L; Häberle L; Wunderle M; Hoyer J; Reis A; Schulz-Wendtland R; Beckmann MW; Lux MP
    Breast; 2017 Apr; 32():186-191. PubMed ID: 28214786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
    Hurry M; Eccleston A; Dyer M; Hoskins P
    Int J Technol Assess Health Care; 2020 Apr; 36(2):104-112. PubMed ID: 32423520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer.
    Einbeigi Z; Bergman A; Kindblom LG; Martinsson T; Meis-Kindblom JM; Nordling M; Suurküla M; Wahlström J; Wallgren A; Karlsson P
    Eur J Cancer; 2001 Oct; 37(15):1904-9. PubMed ID: 11576847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
    Narod SA; Rodríguez AA
    Salud Publica Mex; 2011; 53(5):420-9. PubMed ID: 22218796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.